Review ArticlesMolecular Classification of Large B-Cell Non-Hodgkin LymphomaBojarczuk, Kamil PhD; Wienand, Kirsty PhD; Chapuy, Bjoern MDAuthor Information From the Department of Hematology and Oncology, University Medical Center Göttingen, Germany. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. Reprints: Bjoern Chapuy, MD, University Medical Center Göttingen, Robert-Koch Str. 40, 37075 Göttingen, Germany. E-mail: Bjoern.Chapuy@med.uni-goettingen.de. The Cancer Journal: 7/8 2020 - Volume 26 - Issue 4 - p 357-361 doi: 10.1097/PPO.0000000000000464 Buy Metrics Abstract Large B-cell lymphomas (LBCLs) represent a frequent but clinically and morphologically heterogeneous group of tumors. Technological advances over the last 2 decades prompted the development of new classification schemas to sharpen diagnoses, dissect molecular heterogeneity, and identify rational treatment targets. Despite increased molecular understanding of these lymphomas, the clinical perspectives of patients largely remain unchanged. Recently finished comprehensive genomic studies discovered genetically defined LBCL subtypes that predict outcome, provide insight into lymphomagenesis, and suggest rational therapies with the hope of generating patient-tailored treatments with increased perspective for patients in greatest need. Here, we summarize notable examples of how high-throughput technologies aided in better molecular understanding of LBCLs and provided examples of rationally designed targeted treatments. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
